Pneumonia substantially raises the risk of blood clots, both in the lungs and in the deep veins of the legs. A large case-control study found that people with a recent pneumonia episode were almost four times more likely to develop a venous blood clot than those without pneumonia, even after accounting for other risk factors like immobility and age.1Journal of Thrombosis and Haemostasis. Pneumonia, thrombosis and vascular disease The connection runs deeper than bedrest and hospital stays, and it touches every major type of pneumonia, from bacterial to viral to atypical forms.
How Common Are Blood Clots During Pneumonia
The numbers are sobering, especially in severe cases. Among hospitalized patients with severe community-acquired pneumonia who were already receiving preventive blood thinners, roughly one in three still developed deep vein thrombosis in the lower extremities.2PubMed Central. Deep vein thrombosis in severe community-acquired pneumonia patients undergoing thromboprophylaxis: Prevalence, risk factors, and outcome That finding is striking because these patients were already on preventive anticoagulant therapy, meaning the clotting drive from pneumonia was strong enough to overcome standard prophylaxis in a significant share of patients.
The fourfold increase in venous clot risk found in the case-control data held up after adjusting for the obvious confounders: sex, age, classical clotting risk factors, lifestyle habits, and immobilization.1Journal of Thrombosis and Haemostasis. Pneumonia, thrombosis and vascular disease In other words, pneumonia itself is contributing to clot formation, not just the fact that sick people tend to lie in bed. The risk is not confined to deep vein thrombosis either. Pulmonary embolism, where a clot travels to or forms within the lung’s blood vessels, is another well-documented complication, and the two conditions can be maddeningly difficult to tell apart when they overlap with pneumonia’s own lung symptoms.
Why Pneumonia Pushes the Body Toward Clotting
To understand why a lung infection triggers clots, it helps to know that the body’s immune response and its clotting system are deeply intertwined. Researchers sometimes call this crosstalk “immunothrombosis,” a process in which the same immune cells fighting infection simultaneously nudge the blood toward forming clots. In mild infections this can actually help wall off pathogens. But in pneumonia, especially severe cases, the process spirals out of control.
Several mechanisms work in parallel. First, inflammation ramps up clot-promoting signals. Inflammatory molecules such as IL-1, IL-6, and TNF-α directly increase the production of clotting factors while simultaneously suppressing the body’s natural clot-dissolving machinery.3American Journal of Respiratory Cell and Molecular Biology. Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19 The result is a double hit: more clot formation and less clot breakdown.
Second, neutrophils, a type of white blood cell that floods into infected lung tissue, release web-like structures called neutrophil extracellular traps. These structures are meant to snare bacteria, but they also abnormally activate clotting pathways and damage the inner lining of blood vessels.4PubMed Central. Impact of Neutrophil Extracellular Traps on Thrombosis Formation: New Findings and Future Perspective In sepsis-associated lung injury, these traps have been shown to cause endothelial cell damage along with a surge in tissue factor, a protein that kicks the clotting cascade into high gear.5Cell Death Discovery. Neutrophil extracellular traps contribute to immunothrombosis formation via the STING pathway in sepsis-associated lung injury
Third, pneumonia causes low oxygen levels in the blood. Hypoxia is itself a potent trigger for clotting. When oxygen drops, the body activates transcription factors that ramp up tissue factor production in immune cells and blood vessel walls while simultaneously suppressing enzymes that dissolve clots.6PubMed. Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis Animal studies confirm that thrombus formation increases under hypoxic conditions, yet current clot-prevention drugs do not directly target these oxygen-responsive pathways.7PubMed. The stimulation of thrombosis by hypoxia This is one reason why pneumonia patients who develop significant oxygen problems seem especially vulnerable to clots.
All three mechanisms, inflammation, neutrophil trap formation, and hypoxia, feed into each other. As researchers have described, a feedback loop can develop within the small vessels of the lungs: tissue damage triggers inflammation, inflammation worsens clotting, clotting worsens oxygen delivery, and falling oxygen levels drive more clotting.8The Lancet Rheumatology. Pulmonary intravascular coagulopathy in COVID-19 pneumonia Breaking that cycle is a central challenge in managing severe pneumonia.
Different Pathogens, Different Clotting Risks
Not every pneumonia-causing organism pushes the clotting system in exactly the same way. While the inflammatory and hypoxic mechanisms described above are common to most forms of pneumonia, individual pathogens add their own wrinkles.
Bacterial Pneumonia
Streptococcus pneumoniae, the most common cause of bacterial community-acquired pneumonia, has a direct relationship with platelets. Research has shown that this bacterium activates platelets through a specific receptor called TLR2, triggering a signaling chain that leads to platelet clumping and dense-granule release, both of which promote clot formation.9Journal of Thrombosis and Haemostasis. Invasive Streptococcus pneumoniae trigger platelet activation via Toll‐like receptor 2 Beyond this receptor-mediated pathway, pneumococcal bacteria also produce toxins such as pneumolysin, which can punch holes in cell membranes and further disturb normal platelet function.10PubMed Central. Platelets, Bacterial Adhesins and the Pneumococcus So with bacterial pneumonia, you get the body’s own overactive immune response promoting clots, plus the bacterium itself directly activating platelets.
Viral Pneumonia
Viral infections can affect every aspect of the clotting system: platelet behavior, the coagulation cascade, and the clot-dissolving pathways. As a result, viral pneumonia can produce thrombosis, disseminated intravascular coagulation, hemorrhage, or sometimes a mix of all three.11PubMed Central. Review: Viral infections and mechanisms of thrombosis and bleeding COVID-19 put this relationship under a spotlight. In severe SARS-CoV-2 pneumonia, activated neutrophils and monocytes interact with platelets and the coagulation cascade to drive clot formation within both small and large blood vessels, a textbook case of immunothrombosis.12PubMed Central. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 While COVID-19 attracted the most attention, influenza and other respiratory viruses also carry elevated clotting risk during severe illness.
Mycoplasma Pneumoniae
Mycoplasma pneumoniae, sometimes called “walking pneumonia” because it is often milder, has a unique clotting mechanism. Some patients with Mycoplasma infection develop transient antiphospholipid antibodies, including anticardiolipin and lupus anticoagulant antibodies. These antibodies react with phospholipid components of cell membranes and promote thrombus formation. They are typically transient, disappearing within three to six months after the infection resolves.13PubMed Central. Thrombosis associated with mycoplasma pneumoniae infection Case reports have documented unexpected complications like splenic infarcts in children with Mycoplasma infection and transient antiphospholipid antibodies, a pairing that had not been previously recognized.14PubMed. Mycoplasma pneumoniae, splenic infarct, and transient antiphospholipid antibodies: a new association? The takeaway is that even “mild” pneumonia can trigger clotting complications through mechanisms that are entirely different from what you would see in a severe ICU case.
Tiny Clots You Cannot See on Standard Imaging
When clinicians look for blood clots, they usually reach for a CT angiogram that can visualize blockages in the larger pulmonary arteries. But pneumonia frequently causes clotting at a scale that standard imaging misses entirely. In COVID-19 pneumonia, specialized dual-energy CT scans revealed significant areas of lung tissue that had lost blood flow even though no visible clot appeared in the pulmonary arteries.15PubMed Central. COVID-19 pneumonia: microvascular disease revealed on pulmonary dual-energy computed tomography angiography These “microthromboses,” tiny clots forming within the smallest blood vessels of the lung, likely contribute to the oxygen problems and breathlessness that many pneumonia patients experience even when scans appear relatively clear.
This distinction matters practically. A patient with persistent shortness of breath after pneumonia whose CT angiogram shows no large clot may still have microvascular clotting that is affecting gas exchange. The standard diagnostic tools were not designed to catch it. Autopsy studies during the COVID-19 pandemic confirmed widespread microthrombosis in lung tissue that had not been apparent on pre-mortem imaging, reinforcing that the scope of clotting in pneumonia goes well beyond what routine tests reveal.
Why Pneumonia and Pulmonary Embolism Are Easy to Confuse
Pneumonia and pulmonary embolism share an overlapping set of symptoms: sudden shortness of breath, chest pain, cough, fever, and elevated heart rate. They can even look similar on imaging. A wedge-shaped opacity on a CT scan is classically associated with pulmonary embolism, but it can also appear in pneumonia, making the two hard to distinguish.16Journal of Translational Medicine and Epidemiology. The Diagnostic Dilemma between Pulmonary Embolism with Positive Chest Imaging and Pneumonia: A Case Report and Literature Review To complicate matters further, the two conditions often occur together, since pneumonia itself promotes clot formation. When CT imaging cannot make the distinction, a ventilation-perfusion scan can help: if a segment of lung has preserved airflow but no blood flow (a “mismatch”), pulmonary embolism is likely; if both airflow and blood flow are absent together (a “match”), pneumonia is more probable.
D-dimer, a blood test often used to screen for blood clots, adds another layer of confusion. D-dimer levels rise in both pneumonia and pulmonary embolism, and research shows that D-dimer levels in community-acquired pneumonia can be just as high as those seen in pulmonary embolism, undermining the test’s ability to distinguish between the two conditions.17PubMed Central. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis In one analysis, D-dimer levels fell as the infection resolved, suggesting they reflected the inflammatory process rather than a separate clotting event. The correlation between D-dimer and validated thrombosis risk scores was weak, further limiting D-dimer’s usefulness as a standalone guide for deciding whether a pneumonia patient needs anticoagulation.
Preventing and Managing Clots During Pneumonia
Given the elevated clotting risk, hospitalized pneumonia patients typically receive some form of preventive anticoagulation, usually low-dose heparin or similar drugs. But calibrating the dose is tricky. During the early COVID-19 pandemic, some clinicians pushed for higher, even therapeutic-dose anticoagulation to counter the intense clotting seen in severe cases. Subsequent clinical studies tempered that enthusiasm, finding that escalating to full therapeutic doses in critically ill patients increased bleeding without clearly improving outcomes.18The Lancet Respiratory Medicine. Pathophysiology, thrombotic complications, and management of coagulopathy in COVID-19
The difficulty lies in the fact that severe infections simultaneously increase both clotting risk and bleeding risk. Systemic inflammation depletes clotting factors and platelets even as it promotes abnormal clot formation, meaning the same patient can be at risk for both a dangerous clot and a dangerous bleed.19JAMA Network Open. Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy There is no universal “right dose” of blood thinner for a patient with severe pneumonia. Decisions tend to be individualized based on severity of illness, existing bleeding risk factors, kidney function, and sometimes close monitoring of clotting labs.
For less severe pneumonia managed at home, the risk of blood clots is lower but not zero. General prevention strategies include staying as mobile as possible, staying well-hydrated, and being aware that new-onset leg swelling, chest pain, or a sudden worsening of breathlessness warrants prompt medical evaluation. People with pre-existing clotting risk factors, such as a history of prior blood clots, recent surgery, hormonal therapy, or known clotting disorders, should discuss their pneumonia-related clot risk with their care team.
Could Aspirin Help
Alongside standard blood thinners, researchers have investigated whether aspirin, an antiplatelet drug rather than a true anticoagulant, might help pneumonia patients. A retrospective analysis of a large critical-care database found that aspirin use in patients with community-acquired pneumonia was associated with lower 28-day mortality. After matching patients for similar characteristics, the mortality rate among aspirin users was about 20%, and the risk of death was roughly 25% lower compared to non-users.20PubMed Central. Aspirin reduces the mortality risk of patients with community-acquired pneumonia: a retrospective propensity-matched analysis of the MIMIC-IV database
These findings are intriguing, but the evidence is observational, not from a randomized trial. Patients who were already taking aspirin (often for heart disease prevention) may differ from non-users in ways that statistical matching cannot fully capture. Still, the results align with the biological plausibility: if bacteria like S. pneumoniae directly activate platelets, then blocking platelet aggregation with aspirin could theoretically help break the cycle. Whether aspirin should be routinely added to pneumonia treatment remains an open question that needs prospective trial data to answer.
Children Are Not Exempt
Blood clots in children are rare in general, which makes clinicians less likely to suspect them. But pneumonia, especially Mycoplasma pneumoniae pneumonia, can cause clotting events even in pediatric patients. Research has identified several risk factors that raise suspicion for pulmonary embolism in children with Mycoplasma pneumonia: fever lasting more than about a week, elevated D-dimer, elevated immunoglobulin A, chest pain, symptoms outside the respiratory tract, and certain airway complications. Combining these markers improved diagnostic accuracy substantially.21Scientific Reports. Clinical characteristics and risk factors of pulmonary embolism with Mycoplasma pneumoniae pneumonia in children
The challenge is that many of these red flags, like prolonged fever and elevated inflammatory markers, are common in severe childhood pneumonia regardless of whether clotting is occurring. Parents and clinicians alike tend to attribute worsening symptoms entirely to the infection itself. Clotting complications in children with pneumonia are uncommon enough that they are easy to miss, but serious enough that they need to stay on the radar when recovery stalls or unusual symptoms appear.
The Risk Does Not End When the Infection Clears
One commonly overlooked dimension of pneumonia-associated clotting is that the risk persists after the acute infection resolves. In the case-control study that found the fourfold increase in venous clot risk, pneumonia occurring in the year before a clotting event was significantly more common among patients who developed clots than among controls: present in about 7% of clot patients versus roughly 1.5% of the comparison group.1Journal of Thrombosis and Haemostasis. Pneumonia, thrombosis and vascular disease This suggests that the prothrombotic effects of pneumonia linger well beyond the days of active fever and cough. Possible explanations include residual endothelial damage, ongoing low-grade inflammation, and deconditioning from extended illness and recovery. For people recovering from a severe bout of pneumonia, the weeks and months after hospital discharge are a window of continued vulnerability, and new symptoms like unexplained leg swelling or sudden shortness of breath should not be dismissed as “normal recovery.”
When a Pneumonia Patient Should Worry About Clots
If you or someone you are caring for has pneumonia, certain warning signs should prompt immediate medical attention for possible blood clots:
- Sudden worsening of breathlessness: Breathing difficulty that is out of proportion to what the infection alone would explain, especially if it comes on abruptly rather than gradually.
- Chest pain on breathing in: Sharp or stabbing pain that gets worse with deep breaths (pleuritic pain) can indicate a pulmonary embolism, though it also occurs in pneumonia itself.
- One-sided leg swelling: Swelling, warmth, or redness in one leg, especially the calf, may indicate a deep vein thrombosis.
- Rapid heart rate without an obvious cause: A heart rate that stays elevated after fever comes down could be a sign that the heart is compensating for a clot reducing blood flow through the lungs.
- Coughing up blood: While small amounts of blood-tinged sputum can happen with pneumonia, frank blood or increasing amounts should be evaluated urgently.
None of these symptoms are exclusive to blood clots; pneumonia alone can produce all of them. The key is a change in pattern: a sudden step-change in severity, a new symptom appearing days into treatment, or a failure to improve on appropriate antibiotics or antivirals. Clinicians may need to use CT angiography, ventilation-perfusion scanning, or lower-extremity ultrasound to sort out what is happening, especially since D-dimer testing alone cannot reliably distinguish between active infection and clot formation in the setting of pneumonia.